日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME

对于接受 EXTREME 方案治疗后病情进展的复发或转移性头颈部鳞状细胞癌患者,可使用西妥昔单抗联合紫杉醇或单用紫杉醇。

Chevalier, Thomas; Daste, Amaury; Saada-Bouzid, Esmaa; Loundou, Anderson; Peyraud, Florent; Lambert, Tiphaine; Le Tourneau, Christophe; Peyrade, Frédéric; Dupuis, Charlotte; Alfonsi, Marc; Fayette, Jérôme; Reure, Juliette; Huguet, Florence; Fakhry, Nicolas; Toullec, Clémence; Salas, Sébastien